• Company Overview
  • Accreditation & Patents
  • Governance
  • Vacancies

About Synapse

Synapse Electroceutical is a leading UK medical technology company with over 15 years experience of developing and producing medical devices grounded in Synapse's unique, clinically proven and patented electroceutical technology.

Incorporated in January 2003, our early work focused on product development, defining intellectual property rights, and refining and securing patents. Sustained growth followed; we now have a strong and committed workforce, our products are recognised for their clinical excellence and value for money across the medical and sport sectors in the UK and worldwide.

Our key product is Accel-Heal, an externally applied electroceutical (EAE) for the treatment of complex wounds. It is a 12 day treatment course consisting of six, battery powered, 48 hour single use units, applied consecutively. Accel-Heal is the only EAE proven to expedite effective healing by changing physiological processes implicated in wound complexity; it targets a key underlying cause of why wounds do not heal and become complex. Accel-Heal EAE is listed within the Drug Tariff, and available for clinical prescribing in England, Wales, Scotland and Northern Ireland. Visit the Accel-Heal product website at www.accelheal.com to find out more.

Developed to provide ease and simplicity of clinical application, based on Synapse's unique electroceutical technology, Accel-Heal EAE improves treatment outcomes, increases healing rates and significantly contributes to treatment cost savings.

Contact us here if you would like to find out more about Synapse, Accel-Heal EAE, our unique electroceutical technology or products in development.

Synapse quality and excellence

All Synapse electroceutical products are designed and manufactured to conform with the highest standards of quality and safety.

All our products adhere to the quality standards dictated by the International Organisation for Standardization (ISO), Medical Device Directive (MDD), Medical Device Classification and carry the Conformité Européenne (CE) marking. In 2007 Synapse Micro-Current Ltd achieved ISO 9001 Quality Management Systems and ISO 13485 accreditation for the design and manufacture of medical devices for sport and medical applications.  In addition, Synapse has over 50 patents already granted and several pending in key territories of the world as well as a number of registered trademarks.

Synapse Electroceutical medical products are officially certified as Class IIA devices under the medical directive 93/42/EEC. All have full Medical Devices Directive approval under ISO 13485:200 which while ensuring patient safety, compliance with regional and national laws and maintaining efficiency within the organisation, certifies the product's suitability for European markets.

Accel-Heal®  carries the CE mark having been tested and approved by Notified Body 0120 Accel-Heal® is manufactured to ISO 13485:2003 for the design and manufacture of medical devices and our Quality Management System holds ISO 9001:2008 accreditation.
Click here to download a (pdf) copy of the ISO 13485 certification
Click here to download a (pdf) copy of the ISO 9001 certification
Click here to download a (pdf) copy of the ISO 93/42 EEC certification
Click to download a (pdf) copy of the declaration of conformity
All Synapse Electroceutical products carry the CE marking.
For a comprehensive document covering hazards, contra-indications and warranty please visit this link

The Synapse Electroceutical Accel-heal® unit is classified as Class IIA medical devices, having been tested and approved by Notified Body 0120 at meeting the standards of the Medical Devices Directive and the ISO 13485 management system.
iso




Therapeutic Goods Administration (TGA) Approval for Accel-Heal in Australia.

About our people

Executive Directors

John Gildersleeve
Chief Executive Officer

John has over 15 years experience leading business start ups and business development to achieve exceptional profit growth and public floatation across sectors including e-commerce, entertainment, communications and now medical devices. Under his leadership Synapse Electroceutical has gone from strength to strength, becoming established as a leading provider of technology based medical devices to the sport and wound care sectors. Email John

Andrew Wildman ACA
Chief Financial Officer

A qualified accountant since 1994, Andrew’s experience includes leading the AIM IPO teams at Deloitte and Ernst & Young where he worked with numerous entrepreneurial businesses, including pharma and biotech companies, on successful IPOs. Email Andrew

Non Executive Directors

Jonathan Pockson
Non Executive Chairman

Jonathan has over twenty years experience as a commercial chartered accountant in the pharmaceutical and investment banking industries. His experience spans the executive management of both publicly quoted and private companies and has been directly responsible for raising over £130 million for the biotechnology companies with whom he has been involved. Responsibilities have included, managing the operations, finance, business development, communications, corporate governance and secretarial functions and also the Capital Markets interface on both sides of the Atlantic.

Martin Zapico
Non Executive Director

Martin is a Managing Director at ICAP. Previously a Managing Director at Morgan Stanley for over 20 years, where he was the Global Head of the Securities Lending, Equity Swaps and Tax Arbitrage businesses, all of which were voted 'Best of Breed'. Martin is also a Director of the award winning Westminster based Cinnamon Club restaurant.

Craig Morgan
Non Executive Director

Craig was formerly a Managing Director at Morgan Stanley where he worked for 14 years. He is currently pursuing independent business ventures.


It's great working with us

We love working here and know that you would too. Our teams are knowledgable, enthusiastic and committed. 

Current Vacancies

There are currently no vacancies at Synapse.